Influenza
Conditions
Interventions
Adult influenza patients treated with marbaloxavir:None
Adult patients with influenza treated with maoseltamivir:None
Sponsors
The eighth affiliated hospital of Sun Yat-Sen university
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years; Weight >= 60 kg; Gender not limited. 2. Adult patients with influenza who have received treatment with maribavir or oseltamivir.
Exclusion criteria
Exclusion criteria: 1. Significant exacerbation of underlying diseases; 2. Patients with severe influenza; 3. Severe influenza (according to the 2020 WHO Influenza Diagnosis and Treatment Protocol) includes any one of the following: (1) Persistent high fever for > 3 days, accompanied by severe cough, sputum purulence, bloody sputum, or chest pain; (2) Rapid respiratory rate, dyspnea, cyanosis of lips; (3) Mental changes such as slow reaction, lethargy, restlessness, convulsion or convulsion; (4) Severe vomiting, diarrhea, and dehydration; (5) Chest imaging showed large areas of lung exudation and other pneumonia changes; (6) Other clinical conditions requiring hospitalization; 4. Co-infection requiring systemic antimicrobial and/or antiviral therapy (non-influenza) detected by baseline screening; 5. Check the use of anti-influenza drugs (including: maribavir, oseltamivir, zanamivir, peramivir, abidol, favelavir, amantadine and rimantadine) within 30 days before dose; 6. Patients who used traditional Chinese medicine (TCM) with antiviral effect of influenza according to the instructions and with high-level RCT evidence after the onset of symptoms (other TCM used before the visit were recorded as medication history); 7. Patients with severe liver impairment (Child-Pugh class C), renal impairment (creatinine clearance <=50 mL/min); 8. Immunocompromised patients after organ or bone marrow transplantation; 9. Suspected or confirmed COVID-19; 10. Have participated in a drug clinical trial in the past year; 11. Allergy to maribavir/excipients or other contraindications to maribavir; 12. Were considered by the investigator to have other conditions for which maribavir therapy was not appropriate (e.g., patient could not swallow tablets, pregnancy).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Demographic characteristics (including gender, age, height, weight, etc.);Clinical data;Efficacy and adverse reactions;Quantitative detection of influenza virus RNA; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood routine, biochemistry, liver function and renal function;Inflammatory factors;Chest imaging; | — |
Countries
China
Contacts
Public ContactWu Haidong
The eighth affiliated hospital of Sun Yat-Sen university
Outcome results
None listed